Omega Therapeutics IPO Presentation Deck

In vivo poC Data in Oncology Program - NSCLC Statistically significant reduction of tumor growth after IV treatment every five days with OEC candidate in NSCLC xenograft tumor model (H2009) Tumor volume (mm³) 1200- 1000- 800- 600- 400- 200- Negative control OEC candidate Cisplatin Ⓒ2021 Omega Therapeutics, Inc. 10 Day HAHA 20 *HHHH HHH 20 10- P -10- % Body Weight Change from Baseline -20- *OEC candidate, t-test p<0.005; compared to negative control Arrows denote dosing days 10 ↑ Day 20 Negative control OEC candidate Cisplatin 23

View entire presentation